Skip to Main Content

Hello, everyone, and how are you today? We are doing just fine, thank you, despite puffs of moist clouds hovering over the Pharmalot campus. Our spirits are forever sunny, thanks to an insightful saying from the Morning Mayor: Every brand new day should be unwrapped like a precious gift. A useful reminder, yes? So while you tug on the ribbon, here are some items of interest to get you started on a busy day. Hope all goes well and do keep in touch …

A Merck (MRK) cholesterol drug cut the risk of heart attack and death by just 9 percent and caused buildup of the drug in fat tissue, leaving its future uncertain, Reuters says. Known as a CETP inhibitor, the drug is supposed to raise good cholesterol, or HDL, while lowering LDL, or bad cholesterol. Merck has not decided whether to seek regulatory approval. Wall Street has been skeptical about its prospects since top-line study results were released in June.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!